Ultragenyx Pharmaceutical
(NASDAQ:RARE)
$46.82
0[0.00%]
Last update: 4:00PM Get Real Time Here
Consensus Rating1
Overweight
Highest Price Target1
$162.00
Lowest Price Target1
$48.00
Consensus Price Target1
$100.40

Ultragenyx Pharmaceutical Stock (NASDAQ:RARE), Analyst Ratings, Price Targets, Predictions

Ultragenyx Pharmaceutical Inc has a consensus price target of $100.4, established from looking at the 60 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, JP Morgan, and Cantor Fitzgerald on March 18, 2024, February 27, 2024, and February 27, 2024. With an average price target of $95.67 between JP Morgan, JP Morgan, and Cantor Fitzgerald, there's an implied 104.33% upside for Ultragenyx Pharmaceutical Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
2
Nov 23
1
Dec 23
1
Jan
2
Feb
4
1
Mar
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JP Morgan
JP Morgan
Cantor Fitzgerald
Canaccord Genuity
Wedbush

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Ultragenyx Pharmaceutical

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/18/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.8296.5%JP Morgan
Anupam Rama
$88 → $92MaintainsOverweightGet Alert
02/27/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.8287.95%JP Morgan
Cory Kasimov
$84 → $88MaintainsOverweightGet Alert
02/27/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.82128.53%Cantor Fitzgerald
Kristen Kluska
→ $107MaintainsOverweightGet Alert
02/21/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.82137.08%Canaccord Genuity
Whitney Ijem
$110 → $111MaintainsBuyGet Alert
02/16/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.822.52%Wedbush
Laura Chico
$47 → $48MaintainsNeutralGet Alert
02/15/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.82143.49%Cantor Fitzgerald
Kristen Kluska
→ $114ReiteratesOverweight → OverweightGet Alert
01/30/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.8245.24%Baird
Joel Beatty
$57 → $68MaintainsOutperformGet Alert
01/19/2024RAREBuy Now
Ultragenyx Pharmaceutical
$46.82143.49%Cantor Fitzgerald
Kristen Kluska
→ $114ReiteratesOverweight → OverweightGet Alert
12/08/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.8253.78%Wells Fargo
Tiago Fauth
→ $72Initiates → OverweightGet Alert
11/03/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.8279.41%Morgan Stanley
Jeffrey Hung
$90 → $84MaintainsOverweightGet Alert
10/25/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.82177.66%Piper Sandler
Christopher Raymond
$135 → $130MaintainsOverweightGet Alert
10/10/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.8292.23%Morgan Stanley
Jeffrey Hung
$95 → $90MaintainsOverweightGet Alert
09/25/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.82143.49%Cantor Fitzgerald
Kristen Kluska
→ $114ReiteratesOverweight → OverweightGet Alert
08/04/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.82102.9%Morgan Stanley
Jeffrey Hung
$95 → $95ReiteratesOverweight → OverweightGet Alert
08/01/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.8275.14%HC Wainwright & Co.
Ed Arce
→ $82ReiteratesBuy → BuyGet Alert
06/14/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.82105.04%Credit Suisse
Tiago Fauth
→ $96Assumes → OutperformGet Alert
06/07/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.82184.07%Citigroup
Yigal Nochomovitz
$130 → $133MaintainsBuyGet Alert
06/06/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.8270.87%Evercore ISI Group
Liisa Bayko
$60 → $80UpgradeIn-Line → OutperformGet Alert
06/06/2023RAREBuy Now
Ultragenyx Pharmaceutical
$46.828.93%Wedbush
Laura Chico
$48 → $51MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Ultragenyx Pharmaceutical (RARE)?

A

The latest price target for Ultragenyx Pharmaceutical (NASDAQ: RARE) was reported by JP Morgan on March 18, 2024. The analyst firm set a price target for $92.00 expecting RARE to rise to within 12 months (a possible 96.50% upside). 23 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Ultragenyx Pharmaceutical (RARE)?

A

The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ: RARE) was provided by JP Morgan, and Ultragenyx Pharmaceutical maintained their overweight rating.

Q

When was the last upgrade for Ultragenyx Pharmaceutical (RARE)?

A

The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2023 when Evercore ISI Group raised their price target to $80. Evercore ISI Group previously had an in-line for Ultragenyx Pharmaceutical Inc.

Q

When was the last downgrade for Ultragenyx Pharmaceutical (RARE)?

A

The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.

Q

When is the next analyst rating going to be posted or updated for Ultragenyx Pharmaceutical (RARE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.

Q

Is the Analyst Rating Ultragenyx Pharmaceutical (RARE) correct?

A

While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a maintained with a price target of $88.00 to $92.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $46.82, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch